CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence electroencephalogram (EEG) assessment.

Ceribell’s new Neurology Portal enhancements introduce AI-driven algorithms designed to tackle two of the biggest hurdles in EEG evaluation: filtering complex background interference and streamlining the review of lengthy, ambiguous brain recordings.

Deploying EEGs in fast-paced, critical-care environments, such as emergency departments and intensive care units, is inherently difficult. Non-seizure signal disturbances, or artifacts, originating from nearby medical equipment, patient movement, and other physiological signals, are particularly common. Differentiating these sources of interference from the underlying brain signal can make EEG interpretation challenging and time-consuming, even for well-trained neurologists.

Ceribell’s new Artifact Reduction algorithm adds a layer of AI-driven sophistication to the existing approach. Beyond the simple filtering employed by most traditional technologies, the new algorithm recognizes and identifies various artifacts based on dedicated training on its own extensive real-world artifact dataset. This significantly simplifies EEG interpretation for neurologists and improves the point-of-care experience.

Another common challenge arises during the interpretation of lengthy brain recordings. Reviewing these continuous studies is an intensely time-consuming process because findings do not always fall into a binary "seizure" or "no seizure" distinction. Rather, many brain recordings in critical-care patients show abnormal epileptiform patterns that fall along the ictal-interictal continuum.

By analyzing a patient’s EEG recordings and flagging these specific epileptiform abnormalities, Ceribell’s new technology brings clear structure to this complex clinical gray zone, enabling more timely and precise patient care. Instead of wading through hours of raw data, the reviewing neurologist receives an organized, high-confidence starting point with potential pathology already prominently highlighted in the recording viewer, accelerating their read times and increasing efficiency.

Guided by real-world feedback from clinical users and backed by an expansive database of more than one million hours of EEG data, Ceribell continues to evolve its platform to maximize diagnostic confidence and ease hospital operational burdens. This portal update builds upon the Company’s industry-leading POC system, which reduces the time to initiate bedside monitoring from hours to as few as five minutes. The latest enhancements are engineered to seamlessly fit into existing clinical workflows with no software downtime or installation required.